Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31611372 | 0.80 | TLR2 (0.38) | RORCHRH3SIGMAR1CCR5KDM1A | |
| SCHEMBL2342856 | 0.79 | RORC (0.60) | RORCTACR1 | |
| SCHEMBL26303125 | 0.79 | RORC (0.60) | RORCTACR1 | |
| SCHEMBL2335935 | 0.79 | RORC (0.60) | RORCTACR1 | |
| SCHEMBL25498542 | 0.79 | ALDH1A1 (0.49) | RIPK1 | |
| SCHEMBL4094853 | 0.77 | KDM1A (0.48) | RORCHRH3CCR5RIPK1TACR1 | |
| SCHEMBL4096415 | 0.77 | KDM1A (0.48) | RORCHRH3CCR5RIPK1TACR1 | |
| SCHEMBL7494824 | 0.76 | HRH3 (0.38) | RORCHRH3SIGMAR1RIPK1KDM1A | |
| SCHEMBL7938511 | 0.76 | HRH3 (0.38) | RORCHRH3SIGMAR1RIPK1KDM1A | |
| SCHEMBL25785910 | 0.75 | ACHE (0.40) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076349-B2 | Such as (3S,4S)-3-[3-(4-Methanesulfonylbenzyl)-bicyclo[3.2.1]-2,4-dioxo-1 alpha ,3,8-triaza-spiro[4.5]dodec-8-ylmethyl]-4-phenyl-pyrrolidine-1-carboxylic acid tert-butyl ester; inflammation; HIV | VIROCHEM PHARMA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-20090047238-A1 | Novel Spirotropane Compounds And Methods For The Modulation Of Chemokine Receptor Activity | VIROCHEM PHARMA INC. (CA) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047238-A1 | Novel Spirotropane Compounds And Methods For The Modulation Of Chemokine Receptor Activity | AVPR2, CCR5, CXCR1 | USP7 3556/4885RORC 643/4885HRH3 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.